The update followed a higher than expected number of reports of esophageal injury after catheter ablation procedures for ...

Boston Scientific updates Polarx catheter guidelines due to atrio-esophageal fistula risks, highlighting safer usage practices after FDA approval.

The U.S. Food and Drug Administration on Wednesday classified a recall of Boston Scientific's catheters used in a type of ...

TD Cowen raised the firm’s price target on Boston Scientific (BSX ... differentiated products launched from its pipeline. Pick the best stocks and maximize your portfolio: Published first ...

Boston Scientific (NYSE:BSX) designs, manufactures, and markets medical devices for various interventional specialties, offering products for various conditions. The company’s growth prospects ...

Boston Scientific (BSX) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy). Truist raised the firm’s price target on ...

The latest trading session saw Boston Scientific (BSX) ending at $90.43, denoting a -0.03% adjustment from its last day's close. The stock outperformed the S&P 500, which registered a daily loss of 0.

We sell different types of products and services to both investment professionals and individual investors. These products and services are usually sold through license agreements or subscriptions.

Boston Scientific has the Maple Grove Planning Commission ... The proposed expansion “supports the growth” of product lines that the existing building — known as Weaver Lake 4 ...

Boston Scientific (BSX) ended the recent trading ... account the stock's expected earnings growth rate. The Medical - Products was holding an average PEG ratio of 2.58 at yesterday's closing ...